26 years of historical data (2000–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Phibro Animal Health Corporation trades at 26.8x earnings, 62% below its 5-year average of 71.0x, sitting at the 80th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 21%. On a free-cash-flow basis, the stock trades at 30.9x P/FCF, 8% below the 5-year average of 33.7x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.3B | $1.0B | $680M | $555M | $775M | $1.2B | $1.1B | $1.3B | $1.9B | $1.5B | $746M |
| Enterprise Value | $2.0B | $1.7B | $1.1B | $1.0B | $1.2B | $1.5B | $1.4B | $1.6B | $2.1B | $1.7B | $1.1B |
| P/E Ratio → | 26.76 | 21.46 | 279.50 | 16.91 | 15.81 | 21.55 | 31.65 | 23.53 | 28.60 | 23.01 | 9.01 |
| P/S Ratio | 1.00 | 0.80 | 0.67 | 0.57 | 0.82 | 1.40 | 1.33 | 1.55 | 2.27 | 1.94 | 0.99 |
| P/B Ratio | 4.54 | 3.64 | 2.65 | 1.96 | 2.95 | 4.90 | 5.65 | 5.96 | 10.06 | 9.80 | 8.25 |
| P/FCF | 30.87 | 24.85 | 14.66 | — | — | 61.61 | 42.05 | 74.51 | 36.15 | 19.12 | 861.89 |
| P/OCF | 16.11 | 12.97 | 7.76 | 41.69 | 24.48 | 24.21 | 17.93 | 27.29 | 26.57 | 15.06 | 20.05 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Phibro Animal Health Corporation's enterprise value stands at 12.7x EBITDA, 9% above its 5-year average of 11.7x. The Healthcare sector median is 14.2x, placing the stock at a 11% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.34 | 1.11 | 1.05 | 1.24 | 1.86 | 1.80 | 1.88 | 2.61 | 2.28 | 1.42 |
| EV / EBITDA | 12.72 | 11.10 | 12.68 | 9.67 | 10.48 | 14.48 | 14.17 | 15.43 | 17.03 | 14.04 | 9.76 |
| EV / EBIT | 17.97 | 17.12 | 34.50 | 14.21 | 13.87 | 19.74 | 20.77 | 18.27 | 21.27 | 17.85 | 11.38 |
| EV / FCF | — | 41.43 | 24.47 | — | — | 81.44 | 56.84 | 90.06 | 41.66 | 22.44 | 1230.38 |
Margins and return-on-capital ratios measuring operating efficiency
Phibro Animal Health Corporation earns an operating margin of 8.5%. Operating margins have expanded from 7.3% to 8.5% over the past 3 years, signaling improving operational efficiency. ROE of 17.8% indicates solid capital efficiency. ROIC of 9.8% represents adequate returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 30.9% | 30.9% | 30.8% | 30.5% | 30.3% | 32.6% | 32.1% | 32.0% | 32.5% | 32.5% | 31.8% |
| Operating Margin | 8.5% | 8.5% | 5.2% | 7.3% | 8.4% | 9.0% | 8.6% | 8.9% | 12.1% | 12.8% | 11.4% |
| Net Profit Margin | 3.7% | 3.7% | 0.2% | 3.3% | 5.2% | 6.5% | 4.2% | 6.6% | 7.9% | 8.5% | 11.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 17.8% | 17.8% | 0.9% | 12.0% | 19.6% | 25.5% | 16.6% | 27.3% | 38.6% | 53.5% | 137.7% |
| ROA | 4.1% | 4.1% | 0.2% | 3.4% | 5.5% | 6.7% | 4.4% | 7.8% | 10.0% | 10.5% | 15.0% |
| ROIC | 9.8% | 9.8% | 5.5% | 7.6% | 9.3% | 9.5% | 9.9% | 11.5% | 16.9% | 18.0% | 18.4% |
| ROCE | 12.0% | 12.0% | 6.8% | 9.4% | 11.1% | 11.5% | 11.5% | 13.3% | 19.1% | 19.4% | 19.4% |
Solvency and debt-coverage ratios — lower is generally safer
Phibro Animal Health Corporation carries a Debt/EBITDA ratio of 4.9x, which is highly leveraged (52% above the sector average of 3.2x). Net debt stands at $694M ($762M total debt minus $68M cash). Interest coverage of 3.0x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.67 | 2.67 | 2.05 | 1.81 | 1.79 | 1.79 | 2.18 | 1.51 | 1.69 | 2.07 | 3.90 |
| Debt / EBITDA | 4.88 | 4.88 | 5.87 | 4.82 | 4.21 | 4.00 | 4.05 | 3.23 | 2.48 | 2.53 | 3.23 |
| Net Debt / Equity | — | 2.43 | 1.77 | 1.66 | 1.51 | 1.58 | 1.99 | 1.24 | 1.53 | 1.70 | 3.53 |
| Net Debt / EBITDA | 4.44 | 4.44 | 5.08 | 4.43 | 3.55 | 3.53 | 3.69 | 2.66 | 2.25 | 2.07 | 2.92 |
| Debt / FCF | — | 16.58 | 9.81 | — | — | 19.83 | 14.80 | 15.55 | 5.50 | 3.32 | 368.48 |
| Interest Coverage | 3.04 | 3.04 | 1.50 | 4.01 | 6.98 | 7.53 | 4.84 | 6.23 | 7.41 | 5.77 | 5.56 |
Short-term solvency ratios and asset-utilisation metrics
Phibro Animal Health Corporation's current ratio of 2.76x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 1.25x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 3.33x to 2.76x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.76 | 2.76 | 2.94 | 3.33 | 2.97 | 3.04 | 2.87 | 3.02 | 2.90 | 3.14 | 3.15 |
| Quick Ratio | 1.25 | 1.25 | 1.64 | 1.75 | 1.61 | 1.72 | 1.62 | 1.74 | 1.66 | 1.75 | 1.61 |
| Cash Ratio | 0.26 | 0.26 | 0.56 | 0.46 | 0.48 | 0.57 | 0.58 | 0.53 | 0.55 | 0.48 | 0.31 |
| Asset Turnover | — | 0.95 | 1.04 | 1.01 | 1.01 | 0.99 | 1.02 | 1.14 | 1.22 | 1.23 | 1.23 |
| Inventory Turnover | 2.02 | 2.02 | 2.65 | 2.45 | 2.53 | 2.60 | 2.76 | 2.84 | 3.10 | 3.20 | 3.06 |
| Days Sales Outstanding | — | 64.20 | 60.78 | 61.02 | 64.51 | 64.32 | 57.70 | 70.10 | 60.42 | 60.10 | 60.12 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Phibro Animal Health Corporation returns 1.5% to shareholders annually primarily through dividends. A payout ratio of 40.3% is moderate and appears sustainable, balancing shareholder returns with reinvestment capacity. The earnings yield of 3.7% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 1.5% | 1.9% | 2.9% | 3.5% | 2.5% | 1.7% | 1.8% | 1.4% | 0.9% | 1.1% | 2.1% |
| Payout Ratio | 40.3% | 40.3% | 804.7% | 59.6% | 39.5% | 35.7% | 57.9% | 34.0% | 24.8% | 24.5% | 19.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.7% | 4.7% | 0.4% | 5.9% | 6.3% | 4.6% | 3.2% | 4.2% | 3.5% | 4.3% | 11.1% |
| FCF Yield | 3.2% | 4.0% | 6.8% | — | — | 1.6% | 2.4% | 1.3% | 2.8% | 5.2% | 0.1% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 1.5% | 1.9% | 2.9% | 3.5% | 2.5% | 1.7% | 1.8% | 1.4% | 0.9% | 1.1% | 2.1% |
| Shares Outstanding | — | $41M | $41M | $41M | $41M | $41M | $41M | $41M | $40M | $40M | $40M |
Compare PAHC with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| $1B | 26.8 | 12.7 | 30.9 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 | |
| $12B | -51.5 | 16.7 | 42.6 | 43.5% | 5.3% | -3.7% | 1.9% | 4.3 | |
| $33B | 13.1 | 9.8 | 14.5 | 70.5% | 38.0% | 66.0% | 26.9% | 2.3 | |
| $2B | -1.9 | 20.8 | — | 47.1% | 1.1% | -41.9% | 0.2% | 6.8 | |
| $45B | 43.0 | 31.1 | 42.4 | 61.8% | 31.6% | 66.2% | 42.5% | 0.7 | |
| $20B | 40.8 | 9.8 | 16.8 | 6.5% | 2.6% | 2.6% | 4.1% | 3.2 | |
| $13B | 27.8 | 15.8 | 24.9 | 15.6% | 5.9% | 6.0% | 5.3% | 2.9 | |
| $7B | 6.0 | 4.5 | 9.8 | 12.7% | 8.7% | 27.2% | 20.0% | 1.6 | |
| $6B | 5.5 | 8.3 | 4.8 | 25.9% | 11.8% | 12.9% | 6.0% | 4.7 | |
| $159B | 31.9 | 20.2 | 49.2 | 36.5% | 18.8% | 20.5% | 7.8% | 6.0 | |
| $53B | 49.1 | 13.3 | 18.7 | 43.6% | 15.1% | 4.5% | 8.5% | 0.7 | |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Includes 30+ ratios · 22 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PAHC stock.
Phibro Animal Health Corporation's current P/E ratio is 26.8x. The historical average is 21.7x. This places it at the 80th percentile of its historical range.
Phibro Animal Health Corporation's current EV/EBITDA is 12.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 13.1x.
Phibro Animal Health Corporation's return on equity (ROE) is 17.8%. The historical average is 38.9%.
Based on historical data, Phibro Animal Health Corporation is trading at a P/E of 26.8x. This is at the 80th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Phibro Animal Health Corporation's current dividend yield is 1.50% with a payout ratio of 40.3%.
Phibro Animal Health Corporation has 30.9% gross margin and 8.5% operating margin.
Phibro Animal Health Corporation's Debt/EBITDA ratio is 4.9x, indicating high leverage. A ratio above 4x may signal elevated financial risk.